Contact PD/PI: Buse, John B Overall Abstract Since our inception in 2008, the UNC CTSA affiliate, the North Carolina Translational and Clinical Sciences Institute (TraCS) has transformed clinical and translational science at UNC through interdisciplinary research, training, collaboration with partners and stakeholders, and strong engagement across the CTSA consortium. We have built a dynamic regional network of universities, research institutes, health care providers, and >130 community organizations across our state. In the coming funding period, we propose to add NC State University in addition to RTI International and NC A&T University as full partners in our CTSA hub. Our research infrastructure has engaged 3,234 registered members, resolved 11,147 research service requests, trained 63 faculty in our KL2 program, and supported 705 pilot grants, resulting in >$170M in external research funding, and >600 published manuscripts that have been cited >21,000 times. TraCS developed Join the Conquest, an online engagement tool to increase participation in clinical trials, that includes over 6,000 registered participants and over 200 unique research studies. The TraCS 4D Strategic Initiative and KickStart Program have facilitated 141 invention disclosures, 99 patents, 40 licenses, $57M in SBIR/STTR grants, and the creation of 68 new companies. Over the next five years, we will translate the best science from UNC and across the CTSA consortium into creative, effective, and accessible clinical and community interventions, addressing the public health problems of our state and advancing national CTSA goals by completing our Overall Aims.
Aim 1 Workforce Development: Develop and support a skilled and diverse clinical and translational research workforce to advance translational innovations and address healthcare priorities.
Aim 2 Collaboration and Engagement: Engage diverse stakeholders as active partners in translational research, and promote innovative approaches to team science.
Aim 3 Integration: Integrate translational research across the research continuum, disciplines, populations, and throughout the lifespan;
Aim 4 Methods/Processes: Develop and disseminate innovative methods and approaches to address scientific and operational barriers to translating scientific findings.
Aim 5 Informatics: Incorporate cutting-edge informatics tools and methodologies in every aspect of translational research. We believe that we have made exceptional strides in engaging our partners and our community in our activities and are well positioned to advance our mission as a public university CTSA. Going forward, we will further engage our stakeholders in the research process; train the next generation of translational researchers to flourish within interdisciplinary teams; effectively synergize clinical research with health care to identify unmet needs and implement solutions, particularly for populations at risk for poor health outcomes; and rapidly disseminate our findings to our patients, our community partners, and the CTSA Consortium. Project Summary/Abstract Page 176 Contact PD/PI: Buse, John B

Public Health Relevance

The North Carolina Translational and Clinical Sciences Institute (TraCS) is the integrated hub of the NIH Clinical and Translational Science Awards (CTSA) program at the University of North Carolina at Chapel Hill (UNC). Over the next five years, we will apply our expertise and infrastructure to support clinical and translational research, to advance health care for North Carolinians and the national goals of NCATS. Project Narrative Page 177

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
3UL1TR002489-03S1
Application #
10048963
Study Section
Special Emphasis Panel (ZTR1)
Program Officer
Chang, Soju
Project Start
2018-03-30
Project End
2023-02-28
Budget Start
2020-03-06
Budget End
2021-02-28
Support Year
3
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ryan, Patrick B; Buse, John B; Schuemie, Martijn J et al. (2018) Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSER Diabetes Obes Metab 20:2585-2597
Nunnery, Danielle; Ammerman, Alice; Dharod, Jigna (2018) Predictors and outcomes of excess gestational weight gain among low-income pregnant women. Health Care Women Int 39:19-33
Hoffman, Sarah R; Vines, Anissa I; Halladay, Jacqueline R et al. (2018) Optimizing research in symptomatic uterine fibroids with development of a computable phenotype for use with electronic health records. Am J Obstet Gynecol 218:610.e1-610.e7
Khairat, Saif; Obeid, Jihad S (2018) Teleconsent - A New Modality for Informed Consenting. Eur J Biomed Inform (Praha) 14:63-64
Kahkoska, Anna R; Buse, John B (2018) Primum Non Nocere: Refocusing Our Attention on Severe Hypoglycemia Prevention. Diabetes Care 41:1557-1559
Santos Jr, Hudson P; Nephew, Benjamin C; Bhattacharya, Arjun et al. (2018) Discrimination exposure and DNA methylation of stress-related genes in Latina mothers. Psychoneuroendocrinology 98:131-138
Shea, Christopher M; Tabriz, Amir Alishahi; Turner, Kea et al. (2018) Telestroke Adoption Among Community Hospitals in North Carolina: A Cross-Sectional Study. J Stroke Cerebrovasc Dis 27:2411-2417
Okolie, Onyinyechukwu; Irvin, David M; Bago, Juli R et al. (2018) Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection. PLoS One 13:e0198596
Puvanesarajah, Samantha; Nyante, Sarah J; Kuzmiak, Cherie M et al. (2018) PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. Cancer Prev Res (Phila) 11:327-336
Philpott, Hamish; Dellon, Evan (2018) Histologic improvement after 6 weeks of dietary elimination for eosinophilic esophagitis may be insufficient to determine efficacy. Asia Pac Allergy 8:e20

Showing the most recent 10 out of 76 publications